Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.
The interleukin (IL)-5 receptor α antibody benralizumab continues to show a safety profile similar to that observed in the preceding primary trials along with sustained efficacy through 2 years of treatment in patients with severe, uncontrolled asthma, according to the BORA* extension trial.
Abdominal obesity appears to be a significant risk factor for the incidence of late-onset asthma in women but not men, a study reports. Except for waist circumference, metabolic syndrome and its components are not related to the incidence of asthma in both sexes.
New drug applications approved by US FDA as of 01 - 15 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Adherence to inhaled corticosteroids (ICS) among older adults with asthma is relatively low at 40.9 percent, according to a study presented at the recently concluded Singapore Health and Biomedical Congress (SHBC) 2018. Perceived illness timeline and medication beliefs correlate with adherence.
Individuals with asthma may have a tendency to develop obesity, with a higher risk observed among those with adult-onset asthma, according to findings of the European Community Respiratory Health Survey (ECRHS) presented at the recent international congress of the European Respiratory Society (ERS 2018).
Long-term treatment with the anti–interleukin-5 (anti–IL-5) monoclonal antibody mepolizumab provides sustained reductions in exacerbation rate and daily oral corticosteroid (OCS) use in patients with life-threatening or seriously debilitating severe eosinophilic asthma (SEA), according to results of the COSMEX study reported at the European Respiratory Society (ERS) International Congress 2018.
The anti–interleukin-5 (anti–IL-5) agent reslizumab significantly improves disease control and lung function and reduces the need for oral steroid maintenance therapy in patients with severe eosinophilic asthma, results of a real-life study have shown.
A majority of health care professionals (HCPs) have poor knowledge of proper inhaler technique, which may prevent them from effectively teaching patients the correct use of inhalers that is important for effective therapy delivery, reveals a systematic review of 55 studies.
Overall, the risk of lung cancer is higher in former and current smokers with higher concentrations of high sensitivity C-reactive protein (hsCRP), according to a study. Additionally, circulating hsCRP is not associated with the risk of lung adenocarcinoma and may reflect a prediagnostic disease state rather than a causal risk for lung cancer.